An Australian stem cell and regenerative medicine company

August 04, 2020

H.C. Wainwright & Co. Company Update: “Positive CYP-001 Two-Year Long-Term Follow-Up Clinical Data; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics



June 24, 2020

H.C. Wainwright & Co. Company Update: “Clinical Progress on Multiple Fronts; Reiterate Buy;”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics

June 24, 2020

Argonaut Stockbrokers: “Cynata – A Stem Cell Factory”

View Report

View the latest Argonaut Stockbrokers Snapshot Research Update for Cynata Therapeutics

January 16, 2020

Shaw and Partners Flashnote: “UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia; ‘Buy’ Rating; Price Target $3.00”

View Report

View the latest Shaw and Partners Research Update for Cynata Therapeutics



December 17, 2019

H.C. Wainwright & Co. Company Update: “Preclinical Sepsis Data Hint at Therapeutic Potential; Reiterate Buy”

View Report

View the latest H.C. Wainwright Research Update for Cynata Therapeutics